TLR3 and neoplasm: Interestingly, TLR3 agonist ARNAX has been demonstrated to induce activation and infiltration of tumor-specific cytotoxic T lymphocytes and relieve the resistance to PD-L1 blockade without systemic production of cytokines or IFNs.